Milestones

Continuous innovation since 1998

Since inception, MicroPort has always strived to create a people-oriented culture, to innovate relentlessly, so that patients around every corner of the world can enjoy longer and healthier lives.

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

2019

SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China.

MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System.

The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be publicated in the Journal of the American College of Cardiology (JACC).

Every 8 seconds, a MicroPort® product was implanted in a patient globally.

2018

Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet.

Tubridge® Vascular Reconstruction Device was launched.

Firehawk® and Firebird2® gained regulatory approval in Taiwan.

Rega® Family Implantable Pacemakers had been implanted.

Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively.

MicroPort® CRM global headquarter was established in Clamart, France.

MicroPort Orthopedics (Suzhou) Co., Ltd. was established.

Every 12 seconds, 1 MicroPort® product is being used somewhere in the world.

2017

Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash.

AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award.

Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval.

The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0.

Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study.

Firesorb® pivotal study FUTURE II trial completed first enrollment.

MicroPort® CardioFlow brought in strategic investors.

MicroPort® EP quoted on NEEQ.

MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors.

MicroPort® Jiaxing park established.

Acquired Brazil distributors to implement localized management on the Brazil market.

2016

New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award.

Columbus® 3D EP Navigation System received CFDA approval.

MicroPort Scientific India Private Ltd. Established.

MicroPort® Suzhou park established.

Annual sales exceeded 3 billion HKD.

Every 15 seconds, a MicroPort® product was implanted in a patient globally.

2015

MicroPort® Innovation Platform won State Science and Technology Advancement Award.

Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark.

EVOLUTION® medial-pivot knee system received CFDA approval.

MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line.

MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone.

MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established.

Every 18 seconds, a MicroPort® product is implanted in a patient globally.

2014

Firehawk® rapamycin target eluting coronary stent system received CFDA approval.

WILLIS® clinical application project won State Science and Technology Advancement Award.

Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business.

Acquired drug eluting stent related assets and intellectual properties from Cordis.

Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park.

Annual sales exceeded 2 billion RMB.

Every 20 seconds, a MicroPort® product is implanted in a patient globally.

2013

MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA.

Globalization Strategy Implemented.

2012

Initiated “10+5” Operating Model.

Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established.

Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.

Every 30 seconds, a MicroPort® product is implanted in a patient globally.

2011

MicroPort Medical (Jiaxing) Co., Ltd. was established.

Every 90 seconds, a MicroPort® product is implanted in a patient globally.

Undertook national R&D projects accumulating to more than 100 million RMB.

Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.

2010

MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK).

Annual sales exceeded 100 million USD.

Shanghai MicroPort EP MedTech Co., Ltd. was established.

2009

Firebird2™ coronary drug-eluting stent system received registration approval from SFDA.

Shanghai MicroPort Orthopedics Co., Ltd. was established.

2008

Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented.

Began experimental implementation of "Vertical Integration & Horizontal Connection" management model.

2007

Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award.

2006

Hercule® Thoracic Stent-Graft System received SFDA approval.

Coronary drug eluting stent implants reached over 100,000 units.

2005

Aegis Bifurcated Stent-Graft System was named National key new product.

Annual sales exceeded 100 million RMB.

2004

Firebird™ drug eluting stent system received SFDA approval.

Mustang™ coronary stent system received CE mark.

2003

Officially entered Japan market with PTCA Balloon dilatation catheters.

2002

Received major funding from National Development and Reform Commission.

2001

Moved into new headquarters at 501 Newton Road, Zhangjiang Hi-Tech Park.

Received "Shanghai Hi-Tech Enterprise" honor and business became profitable.

2000

Mustang™ bare metal stent received SFDA approval.

1999

PTCA balloon dilatation catheter received SFDA approval, very first sale made.

1998

Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai.